Various treatments approved by the United States Food and Drug Administration for the management of pulmonary arterial hypertension (PAH) target three of the many pathways implicated in the development of PAH: prostacyclin-, endothelin-1 (ET-1)-, and nitric oxidemediated pathways. The objectives of this manuscript are to provide background information on the role of ET-1 in the pathogenesis of PAH, to provide theoretical considerations for the advantages and disadvantages of dual vs single endothelin receptor antagonists (ERAs) for the management of PAH, and to describe the clinical study results from randomized, double-blind, placebo-controlled trials for the various ERAs. ET receptors (ET A and ET B ) have different densities and distributions throughout the body and are dynamically regulated, such that blockade of ET A and ET B receptors may have different results in normal vs pathological conditions. Although differences in biological effects can be found in studies of isolated cells, blood vessels and animal models, clinical treatment studies have not identified clear differences in efficacy among the various ERAs. The main differences appear to be in safety profiles, with a greater frequency of serum liver function abnormalities occurring with the available dual ET A /ET B antagonist, and possibly higher rates of peripheral edema noted with selective ET A agents. Head-to-head studies will be necessary to resolve the question of whether single vs dual blockade produces better clinical results with fewer side effects in patients with PAH. 
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Summary
Various treatments approved by the United States Food and Drug Administration for the management of pulmonary arterial hypertension (PAH) target three of the many pathways implicated in the development of PAH: prostacyclin-, endothelin-1 (ET-1)-, and nitric oxidemediated pathways. The objectives of this manuscript are to provide background information on the role of ET-1 in the pathogenesis of PAH, to provide theoretical considerations for the advantages and disadvantages of dual vs single endothelin receptor antagonists (ERAs) for the management of PAH, and to describe the clinical study results from randomized, double-blind, placebo-controlled trials for the various ERAs. ET receptors (ET A and ET B ) have different densities and distributions throughout the body and are dynamically regulated, such that blockade of ET A and ET B receptors may have different results in normal vs pathological conditions. Although differences in biological effects can be found in studies of isolated cells, blood vessels and animal models, clinical treatment studies have not identified clear differences in efficacy among the various ERAs. The main differences appear to be in safety profiles, with a greater frequency of serum liver function abnormalities occurring with the available dual ET A /ET B antagonist, and possibly higher rates of peripheral edema noted with selective ET A agents. Head-to-head studies will be necessary to resolve the question of whether single vs dual blockade produces better clinical results with fewer side effects in patients with PAH. ª 2009 Elsevier Ltd. All rights reserved.
Introduction
The treatment of pulmonary arterial hypertension (PAH) improved in 1995 with the approval by the United States (US) Food and Drug Administration (FDA) of the prostacyclin analog epoprostenol. This was followed in 2001 with FDA approval of the dual endothelin receptor antagonist (ERA) bosentan. Two more prostacyclin analogs were approved for use in the US, treprostinil in 2002, and inhaled iloprost in 2004. The phosphodiesterase-5 (PDE-5) inhibitor sildenafil was approved in 2005, and the latest approval in 2007 was for ambrisentan, another ERA. These different treatment options target 3 of the many pathways that have been implicated in the development of PAH: prostacyclin-, endothelin-1 (ET-1)-, and nitric oxide-mediated pathways. 1 The objectives of this manuscript are to provide background information on the role of ET-1 in the pathogenesis of PAH, to provide theoretical considerations for the advantages and disadvantages of dual vs single ERAs for the management of PAH, and to describe the clinical study results from randomized, doubleblind, placebo-controlled trials for the various ERAs.
Endothelin Historical perspective
ET was first reported in 1988 as a novel potent vasoconstrictor peptide with a molecular weight of 2492 Da isolated from porcine endothelial cells. 2 The endothelins are a family of isopeptides named ET-1, ET-2 and ET-3. ET-1 is the most abundant and appears to be the most clinically important form of endothelin. ET is synthesized from preproendothelin (prepro-ET), comprised of 212 amino acids, and is cleaved to yield a 38 amino acid propeptide, big ET ( Fig. 1 ). Big ET is converted to the 21 amino acid peptide ET by endothelin-converting enzymes (ECEs).
Physiological/pathological role
The physiological and pathological roles of ET have been examined by noting where overexpression of ET occurs and by studying the effects of exogenously applied ET. For example, overexpression of ET has been observed in tissue samples from various disease states (PAH, connective tissue disease, pulmonary fibrosis), 3 and in the blood of systemic sclerosis patients with either PH and/or lung fibrosis. 4 In a rat model of PAH induced by hypoxia, increased ET expression was observed within the pulmonary artery but not on the thoracic aorta, suggesting tissue selectivity in the abnormal ET expression. 5 Details of selected studies examining different physiological and pathological effects of ET are listed in Table 1 .
Vasoconstriction
One of the first physiological properties of ET to be observed was vasoconstriction, either as a direct effect on the vasculature or indirectly as facilitated by other vasoconstrictor systems (e.g., the renineangiotensin system or the sympathetic nervous system). In studies conducted in anesthetized squirrel monkeys, ET was found to be more potent and longer acting than angiotensin II in producing vasoconstriction. 6 Other studies have shown that ET-1 is 100 times more potent as a vasoconstrictor than pinephrine.
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Hypertrophy Another physiological/pathological effect of ET is the induction of hypertrophy in a variety of tissues, including cardiomyocytes, 8 cardiac fibroblasts, astrocytes, renal interstitial fibroblasts and mesangial cells, 9 vascular smooth muscle cells, 10 and fibroblasts. 11 For example, in one study conducted in cultured neonatal rat cardiomyocytes, cell surface area more than doubled after treatment with ET (10 À7 M for 48 h) compared with untreated cells, without a change in the number of cardiomyocytes, consistent with cellular hypertrophy. 8 Proliferation ET can also cause proliferation of both vascular smooth muscle cells and fibroblasts. For example, biologically active ET in the bronchoalveolar lavage fluid from patients with systemic sclerosis can stimulate the in vitro proliferation of cultured human fetal lung fibroblasts in a dose-dependent manner. 12 The in vitro proliferative response of human aortic smooth muscle cell to stimulation by platelet-derived growth factor is markedly potentiated by ET. 10 
Inflammation
Another effect of ET is the induction of inflammation through various mechanisms, including increased vascular permeability, the stimulation of pro-inflammatory cytokine production, activation of neutrophils or mast cells, and the promotion of cellular adhesion. Infusion of ET (6 nmol/kg i.v.) induces an inflammatory reaction in rat alveolar tissue characterized by platelet aggregation, vascular congestion, neutrophil activation and resultant endothelial cell injury within the pulmonary circulation. 13 In other experiments, ET induces the secretion of interluekin-6 (an inflammatory cytokine) from vascular smooth muscle cells isolated from human saphenous veins.
14 Finally, the intravenous administration of ET to guinea pigs (0.3 nmol/kg and 1 nmol/kg) can increase vascular permeability as indicated by the extravasation of albumin into the lung. 
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ET receptors
Two subtypes of ET receptors are found in different locations (Table 2) . ET A receptors are expressed on vascular smooth muscle cells and fibroblasts, while ET B receptors are located on vascular smooth muscle cells, endothelial cells, fibroblasts, and macrophages. ET signaling through the ET A receptor results in vasoconstriction, while the ET B receptor can cause both vasodilation or vasoconstriction (Fig. 1) . 16 The relative densities of the ET A and ET B receptors vary between tissues and can be altered by disease. Consequently, it is not possible to confidently infer the net effects of ET-1 signaling simply on the basis of the cell type or location. For example, in vitro autoradiography of explanted lung tissue demonstrated that distal pulmonary arteries from individuals without pulmonary hypertension contained a ten-fold greater proportion of ET B receptors than proximal arteries, indicating that the ET A and ET B receptors are differentially distributed in human pulmonary arteries. 17 Upregulation of ET B receptors has also been demonstrated within the pulmonary vasculature, interstitium, and airways of scleroderma patients with pulmonary fibrosis. 18 An increase in ET A receptor density has been reported in the pulmonary arteries and parenchyma of patients with congenital heart disease. 19 The expression of both ET B mRNA transcripts and protein are increased in biopsy samples taken from patients with thromboembolic PH as compared to control lung tissue from donors without PH. By contrast, ET A gene and protein expressions in these diseases tissues were unchanged as compared to control. 20 In other cases it appears that the expression of both ET receptors can be altered by disease, but without a concomitant change in their relative densities. For example, despite a two-fold increase in receptor in PAH patients relative to controls and an associated increase in ligand binding, the relative proportions of the ET A and ET A receptors on distal pulmonary arteries were not altered within explanted lung tissues. Anesthetized squirrel monkeys were studied with Doppler flow-probes to measure blood flow in the renal, mesenteric and iliac vascular beds with application of ET.
All three vascular beds were constricted with i.v. injection of ET. In the kidney, blood flow was almost abolished and the effect of ET was sustained for up to 2 h and more.
Hypertrophy
Ito et al. 8 Cultured neonatal rat cardiomyocytes were examined by Northern blot analysis.
Cell surface area more than doubled after treatment with ET (10 À7 M for 48 h) compared with untreated cells; however, the number of cardiomyocytes did not change. These results suggest cardiac hypertrophy. Proliferation Cambrey et al. 12 Bronchoalveolar lavage fluid was obtained from patients with systemic sclerosis and added to a culture of fibroblasts.
Bronchoalveolar lavage fluid stimulated proliferation of in vitro human fetal lung fibroblasts in a dosedependent manner.
Yang et al. 10 Human aortic smooth muscle cells were cultured and cell proliferation was assayed by [3H]thymidine incorporation.
ET was a co-mitogen because it markedly potentiated the proliferative effects of platelet-derived growth factor.
Inflammation
Helset et al. 13 The time sequence for morphological changes induced by ET-1 in rat alveolar tissue was examined using morphometric analysis based on lung transmission electron micrographs.
The following changes occurred in the pulmonary circulation: platelet aggregation, vascular congestion, and neutrophil activation leading to endothelial cell injury. Morphological signs of injury could be seen on the endothelial cells.
Browatzki et al. 14 Confluent vascular smooth muscle cells isolated from human saphenous veins were incubated with ET for 24 h.
ET-induced secretion of interluekin-6, an inflammatory cytokine, in a concentration-dependent manner.
Filep et al. 15 Bolus i.v. injections of ET-1 (0.1e1 nmol kg
À1
) were given to anesthetized guinea pigs.
Albumin extravasation (quantified by Evan's Blue due binding) was observed in the trachea, upper bronchi, and lower bronchi for each ET dose when compared with control. The extravasation occurred in a dosedependent manner.
Physiological role of ET receptors
The two ET-1 receptors exhibit somewhat different physiological roles. ET A primarily mediates vasoconstriction and proliferation. On smooth muscle cells, ET B mediates vasoconstriction. ET B is also responsible for the removal of ET-1 from plasma. 21 Activation of endothelial ET B receptors stimulates the release of NO and prostacyclin, 22 prevents apoptosis, 23 inhibits ECE-1 expression in endothelial cells and plays a role in endothelial-dependent vasodilatation. 24 ET B may play a role in ET-mediated inflammation. Binding of ET-1 or the ET B -selective ET-3 to this receptor can induce endothelial cell transcription of pro-inflammatory mediators. 25 Incubation of cultured human monocytes with ET also induced expression of inflammatory cytokines (e.g., TNFa). These cells expressed ET B and not ET A , and the effect was inhibited by co-incubation of cells with bosentan, suggesting the pro-inflammatory activity was mediated by ET B . 26 
Cross-talk between ET A and ET B receptors
Multiple animal models suggest that significant cross-talk occurs between the ET A and ET B receptors in certain pathologic states. 27 Such cross-talk might allow one receptor to compensate for blockade of the other. For example, the ET B receptor may adopt functions of the ET A receptor under conditions of selective ET A blockade, 28 suggesting that in some cell systems the inhibition of both receptors may be needed for maximum inhibition. 27 The net effect may be difficult to predict, however, as antagonism of both receptors may have either additive or synergistic effects compared with single receptor blockade. 29 
Heterodimers with ET A and ET B receptors
The ET A and ET B receptors are G-protein coupled receptors (GPCRs) belonging to the rhodopsin class A of seven transmembrane proteins. 30 GPCR dimerization may be required for the proper functioning of some receptors, such as the GABA B receptor. 31 Even GPCRs that do not absolutely require dimerization for functional activity may still associate with other GPCR subtypes, which might alter receptor pharmacology, signaling, or internalization. Indeed, heterodimerization may be an explanation for the cross-talk that is observed in various signaling pathways. 32 Another possibility is that many GPCRs form constitutive dimers in the endoplasmic reticulum and dimerization may be required for trafficking to the cell surface. 33 Functional heterodimers could be a possible explanation for the pharmacologic complexity that has been observed for the ET B receptor that cannot be accounted for by the molecular structure of cloned receptors. 34, 35 Various lines of evidence suggest that ET A and ET B can form functional heterodimers (Fig. 2) . 36 The existence of heterodimers is supported by the observation that ET-1 is a bivalent ligand, which binds to the ET A receptor via its N terminus and to the ET B receptor via its C terminus. 37 It has also been suggested that functional heterodimers between ET A and ET B could explain synergistic effects (to be described later) sometimes observed when blocking both ET A and ET B receptors. 38 In several animal models 39, 40 blocking ET A alone has provided some blunting of physiologic ET effects; however, little effect has been seen by blocking the ET B receptor alone. In these models, maximum inhibition was observed with the blockade of both receptors.
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Human arterial vasoconstriction vs vasodilatation
Whether ET A or ET B antagonism results in arterial vasoconstriction or vasodilatation appears to vary according to the model system and vessels studied (Table 4 ). In human internal mammary arteries and radial arteries, the ET B receptor antagonist BQ-788 significantly inhibited ET-1-induced contraction in internal mammary arteries, but not in radial arteries. 29 This was contrasted with the results using the ET A receptor antagonist BQ-610, which produced a much more potent inhibitory effect on ET-1-induced contraction in internal mammary arteries and also potently inhibited the contraction in radial arteries. The authors concluded that ET-1-induced contraction is mediated by both the ET A (major) and the ET B (minor) receptors in internal mammary arteries, but only by the ET A receptor in radial arteries.
A series of experiments on isolated small pulmonary arteries from rats in which myocardial infarctions had been induced showed that dual antagonism with specific ET A and ET B receptor blockers resulted in optimal blockade of vasoconstriction, possibly because the ET A and ET B receptors could form functional heterodimers. 41 Some studies suggest that ET A and ET B receptor antagonism is complimentary and that the results may be different for healthy individuals compared with patients. 42 In an investigation of the possible role of ET-1 in the increased vasoconstrictor tone of hypertensive patients, various antagonists of ET-1 receptors were applied via intraarterial infusion (ET A receptor antagonist and ET B receptor antagonist ). In healthy subjects, BQ-123 alone or in combination with BQ-788 did not significantly modify forearm blood flow. In hypertensive patients, in contrast, BQ-123 increased forearm blood flow and the combination of BQ-123 and BQ-788 resulted in a greater vasodilator response vs BQ-123 alone. These results suggest that both ET A and ET B receptor blockade result in more marked vasodilation (measured by forearm blood flow) in hypertensive patients compared with selective ET A receptor blockade. Other studies suggest that ET A and ET B receptor antagonism is synergistic and that combined ET A /ET B receptor antagonism is required for complete inhibition of ET-1-induced pulmonary artery vasoconstriction in a rat model of PH (isolated perfused rat lungs). 39 The application of these observations in the pulmonary circulation of patients with PAH remains unclear.
Remodeling
A number of studies have examined the effects of specific ET A vs ET B receptor antagonists on properties related to remodeling. Incubation of normal human dermal fibroblasts with ET resulted in the induction of type I collagen synthesis and a decrease in interstitial collagenase expression. 43 ET A blockade normalized collagenase levels, but did not affect the overproduction of collagen. On the other hand, ET B blockade did not affect induction of type I collagen synthesis or interstitial collagenase expression. Both ET A and ET B mediate the proliferation-inducing effects of ET-1 on cultured pulmonary artery smooth muscle cells derived from explanted human lung. 17 
ET A /ET B receptor antagonism
Blockers have been developed that are antagonists of both ET A and ET B receptors (e.g. bosentan) and are considered dual ET antagonists.
Human arterial vasoconstriction vs vasodilatation
In studies of saphenous vein segments, application of bosentan induced in vitro vasodilation (Table 5) . 44 Bosentan (3 mM) significantly augmented acetylcholine (ACh)-induced vasodilation in pre-contracted isolated saphenous vein segments; however, no response was observed in veins denuded of endothelium. Consequently, blockade of ET A /ET B significantly improved endothelial cell-mediated dilation by ACh in saphenous veins.
Remodeling
In a porcine model of PAH (overcirculation-induced model of PAH produced by anastomosis of the left subclavian artery to the pulmonary arterial trunk) and congenital heart disease (CHD), bosentan prevented pulmonary artery changes indicative of remodeling. 45 Bosentan prevented medial thickening, most evident in the smallest arterioles and prevented medial changes associated with overcirculation.
In a rat model of hypoxia-induced PH, bosentan prevents and reverses vascular hypertrophy. 46 Pulmonary artery pressures were nearly returned to control levels, and hypoxia-induced morphological changes within the pulmonary vascular bed regressed. In other experiments, pretreatment with bosentan prevented the development of hypoxia-induced PH. There was complete blockade of the acute pulmonary vasoconstrictor response to acute hypoxia, the chronic hypoxia-induced PH, and pulmonary vascular remodeling. At the same time, there was no effect on systemic arterial pressure.
Inflammation
Bosentan inhibits inflammation in a rat model in which the intratracheal instillation of Sephadex dissolved in saline produces a hypersensitivity reaction and the rapid recruitment of inflammatory cells, an increase in ET and cytokine secretion. 47 Rats pre-treated with bosentan showed markedly attenuated Sephadex-induced peribronchial inflammation.
ET A vs ET A /ET B receptor antagonism
Several studies have examined the effects of selective ET A antagonism compared with dual ET A /ET B antagonism Sato et al. 39 The effects of ET-receptor agonists and antagonists were studied in isolated perfused rat lungs.
In the isolated perfused rat lung, ET- ( Table 6 ). In isolated perfused rat lungs, dual ET A and ET B receptor antagonism inhibited ET-1-induced pulmonary vasoconstriction to a greater extent than ET A receptor blockade alone. 39 In some experimental conditions, ET A and ET B receptor antagonism appears to be complimentary. 40 In a monocrotaline-induced model of PH in rats, survival was greater among animals treated with a dual ET A /ET B receptor Rats with established chronic hypoxic (10% oxygen) PH were studied.
Bosentan reversed hypoxic PH, returned PAP nearly to control levels, and caused regression of hypoxia-induced morphological changes in the pulmonary vascular bed. Pretreatment with bosentan prevented the development of hypoxiainduced PH.
Rondelet et al. 45 In a porcine overcirculationinduced model of PAH (anastomosis of the left subclavian artery to the pulmonary arterial trunk), pulmonary arteries were examined for medial hypertrophy.
Bosentan prevented medial thickening, most evident in the smallest arterioles. This normalization of the medial layer of vessels suggests that bosentan prevented the changes associated with overcirculation in this model.
Shi-Wen et al. 43 Human dermal fibroblasts were incubated with ET in an in vitro cell culture.
Incubation with ET resulted in induction of type I collagen synthesis and decrease in interstitial collagenase expression. Bosentan showed anti-fibrotic effects by abolishing the ET-induced increase in collagen secretion and the ET-induced decrease in collagenase synthesis.
Inflammation
Finsnes et al. 47 In the rat inflammatory airway model, Sephadex was dissolved in saline and given intratracheally. Rats have a natural hypersensitivity to dextran, resulting in a rapid recruitment of inflammatory cells around the Sephadex beads and an increase in ET and cytokine secretion.
Rats pre-treated with bosentan showed markedly reduced Sephadex-induced peribronchial inflammation.
antagonist than an ET A -specific inhibitor. Reduction of right ventricular hypertrophy was seen only in the animals receiving the dual antagonist, suggesting that blockade of both ET A and ET B receptors in rat is required to fully inhibit the deleterious effects of ET-1 in this monocrotaline model. The implications of these experimental findings in human disease, however, are unclear.
Pivotal clinical trials of ERAs
FDA approval of bosentan for the treatment of PAH came from 2 randomized, placebo-controlled trials of patients with PAH functional class (FC) III or IV; for both studies, the primary endpoint was the degree of change in exercise capacity. In Study 351, Channick et al. reported a 76-m improvement in 6 min walk distance (6MWD) with bosentan (n Z 21) compared with placebo (n Z 10) (P Z 0.021) and significant improvements in mean pulmonary artery pressure, cardiac index, and peripheral vascular resistance (P 0.033) as well as both FC (P 0.019) and the time to clinical worsening (P Z 0.033). 48 In the BREATHE-1 (Bosentan Randomized Trial of Endothelial Antagonist Therapy of Pulmonary Hypertension) trial, patients treated with bosentan (n Z 144) had a 44-m improvement in 6MWD compared with those in the placebo group (n Z 69) (P < 0.001). 49 Bosentan also significantly increased the time to clinical worsening (P < 0.002) and improved FC (P-value not given).
FDA approval for ambrisentan came from 2 randomized, double-blind, placebo-controlled trials of patients with PAH (WHO Group I): ARIES-1 (Ambrisentan in PAH) and ARIES-2, both of which had 6MWD as the primary endpoint. 50 In ARIES-1, which compared once-daily doses of 5 mg and 10 mg of ambrisentan to placebo, the placeboadjusted mean change in 6MWD from baseline was 51 m (P < 0.001) for the 10-mg group and 31 m (P Z 0.008) for the 5-mg group. In ARIES-2, which compared once-daily doses of 2.5 mg and 5 mg ambrisentan to placebo, the placebo-adjusted mean change in 6MWD from baseline was 59 m (P < 0.001) for the 5-mg group and 32 m (P Z 0.022) for the 2.5-mg group. Functional class was improved from baseline in ARIES-1 compared to placebo (P Z 0.036) and while similar trends were seen in functional class improvement in ARIES-2 these were not statistically significant (P Z 0.117). When combined data for the 5 mg dose from ARIES-1 and ARIES-2 were analyzed WHO functional class improvement from baseline to week 12 was observed (P Z 0.025), mostly as a result of less functional class deterioration with ambrisentan as compared to placebo. In ARIES-2, improvements in time to clinical worsening compared to placebo were observed for the 5-mg group (P Z 0.008) and 2.5-mg group (P Z 0.005). In ARIES-1, time to clinical worsening did not significantly improve compared to placebo. When these two datasets were combined as adjudicated by the FDA, time to clinical worsening was judged to be significantly improved compared to placebo. 51 The randomized, double-blind, placebo-controlled trials of sitaxsentan are the STRIDE-1 52 and STRIDE-2 53 (Sitaxsentan To Relieve ImpaireD Exercise) trials. In STRIDE-1, 300 mg of sitaxsentan increased the VO 2 max of PAH patients by 3.1% as compared with placebo by 12 weeks of treatment; both 100 mg and 300 mg treatments resulted in 33e35 m improvements in 6MWD, as well as improvements in hemodynamic indices and functional class. 52 In STRIDE-2, treatment of PAH patients with 50 and 100 mg of sitaxsentan resulted in 24 and 31 m increases in 6MWD at 18 weeks. 53 For all three agents, limited information is known about potential drugedrug interactions which might affect their utility. Studies of interactions with warfarin suggest that warfarin levels are modestly reduced in the presence of bosentan, increased in the presence of sitaxsentan, and appear unaltered in the presence of ambrisentan. Sildenafil levels appear reduced in the presence of bosentan but unaltered by ambrisentan. It should be noted, however, that studies of bosentan's interaction with sildenafil have been conducted in healthy volunteers who did not suffer from chronic cardiac, hepatic, or renal insufficiency. Other interactions require more vigorous investigation. The major argument theoretically favoring selective ET A blockade is that ET B is involved in clearing ET-1 from the circulation. Consequently, blocking ET B receptors might be expected to increase plasma ET-1 levels and worsen the symptoms of PAH. In addition, blockade of endothelial luminal side ET B might theoretically decrease NO and prostacyclin production. However, it is important to note that circulating levels of ET-1 may not directly reflect the abluminal paracrine action of ET-1 on smooth muscle cells that is felt to be of primary importance.
Neither argument has yet been tested nor supported by available clinical trial evidence. A review of the clinical trial data indicates that there are no apparent differences in measurable clinical efficacy among the various single and dual ERAs. 54 Head-to-head studies, particularly in different pathological conditions, will be necessary to definitively answer the question whether there are long-term efficacy differences between single and dual ERAs.
There are safety differences between dual and selective ERAs with regard to the development of liver function test abnormalities. Liver aminotransferase level elevations are more common with bosentan than with sitaxsentan and ambrisentan. 55 However, post-marketing surveillance studies of bosentan reveal that permanent or fatal liver damage has not been observed. 56, 57 The use of ERAs can result in the development of worsening of peripheral edema in some patients. 58 In renal mesangial cells, ET-1 produces natriuresis and diuresis via ET A and ET B ; therefore, ERAs could cause edema. 38 However, the incidence of edema during ERA therapy seems to be correlated with both the selectivity and dosage of the ERA. The incidence of peripheral edema was 8% in pivotal trials of bosentan, compared to 5% in placebo patients. 59 Peripheral edema was a commonly reported adverse event in the ARIES trials, with an incidence of 28.4% in the 10-mg group of the ARIES-1 study (compared to 10.6% in the placebo group). 50 When data from the two trials are combined, overall edema rates of 17% were seen in contrast to 11% in the placebo arm. 51 Rates also appear to be greatest for the elderly in these trials, with those >65 years of age demonstrating a 29% incidence of edema vs 4% for placebo patients. The STRIDE-1 study reported the following rates of peripheral edema: placebo, 16%; sitaxsentan 100 mg, 17%; and sitaxsentan 300 mg, 25%. 52 In STRIDE-2, the rates of edema were 8.1% for placebo and sitaxsentan 50 mg, and 11.5% for sitaxsentan 100 mg. 53 In comparing these rates of peripheral edema it is important to recognize, however, that each of these trials (BREATHE-1, ARIES, STRIDE) studied different populations with fewer patients over the age of 65 being studied in the BREATH-1 trial. In addition the trials did not take into account concomitant medications or medical conditions making it difficult to compare these agents in regards to side-effect profiles. As such, firm statements regarding relative frequency of important side effects cannot be made.
If indeed an increased rate of peripheral edema turns out to be more common with ambrisentan than with bosentan or sitaxsentan, one possible explanation for different rates of edema associated with ERAs may not be related to differences in selectivities for the two ET receptors, but instead may reflect differences in affinities to the ET A receptor. According to Table 3 , the ERAs in order of affinity to the ETA receptor are ambrisentan > sitaxsentan > bosentan. When one looks at another GPCR, the dopamine D 2 receptor, differences in affinity of atypical antipsychotics in binding to the D 2 receptor have been related to their propensity to produce side effects. It has been hypothesized that atypical antipsychotics that bind more loosely to the dopamine D 2 receptor (e.g., quetiapine, K i Z 140 nM) are less likely to produce side effects such as motor symptoms or hyperprolactinemia than atypical antipsychotics that bind more tightly (e.g., risperidone, K i Z 1.1 nM compared to a K i value for dopamine of 1.7 nM). 60 The hypothesis is that dopamine released as a neurotransmitter can readily displace quetiapine but not risperidone from D 2 receptors and thus quetiapine is less likely to produce side effects. Similar mechanisms could be occurring in peripheral vascular beds, with bosentan more easily displaced by ET-1 than ambrisentan at ET A receptors, thus resulting in a lower incidence of edema with bosentan.
A potential explanation for the different rates of edema with selective vs dual ERAs may involve the renineangiotensin system. A recent study suggested that the effects of endothelin receptor blockade, beneficial or harmful, may crucially depend on the stage of congestive heart failure (CHF) when therapy is initiated. 61 This study also reported that selective ET A receptor blockade during an early stage of CHF caused sustained Na þ retention by activating the renineangiotensin system and resulted in edema. Thus, selective ET A blockade might be more likely to produce edema in some patients at certain stages of their disease. Other theoretical reasons for different edema tendencies might be in differences in the interactions of the agents with aldosterone and mineralocorticoid receptors, 62 and unstudied interactions with aquaporin-2 and aquaporin-3. 63 Although these mechanisms have been suggested as possibilities, the exact mechanisms for the potential different rates of edema among the ERAs are not known at this time.
There are several caveats that must be offered for the results reported here. Supporting evidence from animal studies may not accurately reflect the physiology of humans in health and disease. In addition, results observed for ETreceptor blockade in one region of the body may not be applicable to another region. In vitro findings in contrived experimental models may not offer fidelity to the clinical state of PAH. Finally, results observed under normal conditions may not be applicable to pathological conditions and visa versa.
In conclusion, ET receptors have different densities and distributions throughout the body, which are dynamically up-and down-regulated in a still not-adequately-studied manner, and blockade of ET A and ET B receptors may render different results in normal vs pathological conditions. Clinical trial data do not indicate any apparent differences in short-term efficacy between dual and single ET-receptor blockade. Dual blockade appears less likely to produce edema as a side effect, although the elderly population allowed in ARIES-1 and ARIES-2 was not studied in either of the double-blind, placebo-controlled trials of bosentan making definitive statements about edema prevalence between the agents tenuous. In addition these trials did not control for associated disease states or medications that might have altered the presence of edema. Dual blockade appears more likely to induce LFT abnormalities. Head-tohead studies will be required to completely answer these questions of relative efficacy and relative safety profiles of single vs dual ERAs.
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